Translationally, this co-occurrence suggests that TIGIT-high/IFN-g-high CRC tumors may define a clinically actionable subgroup characterized by pre-existing immune activation but incomplete tumor rejection, in which a therapeutic strategy based on inhibitory signaling could be potentially beneficial. This evidence concerns the gene IFNG and neoplasm.